Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
NDC Package 68180-604-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Desvenlafaxine Succinate tablets is desvenlafaxine is used to treat depression. This formulation utilizes a tablet, film coated, extended release delivery system. Marketed by Lupin Pharmaceuticals, Inc., this product is identified by NDC 68180-604 and is authorized under FDA application ANDA204172.

Identification & Billing

NDC Package Code
68180-604-06
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
68180-604
11-Digit Billing Format
68180060406
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 1607617 - desvenlafaxine succinate 25 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1607617 - 24 HR desvenlafaxine succinate 25 MG Extended Release Oral Tablet
  • RxCUI: 1607617 - desvenlafaxine 25 MG (as desvenlafaxine succinate 38 MG) 24HR Extended Release Oral Tablet
  • RxCUI: 1874553 - desvenlafaxine succinate 100 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1874553 - 24 HR desvenlafaxine succinate 100 MG Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Desvenlafaxine Succinate
Non-Proprietary Name
Desvenlafaxine Succinate
Substance Name
Desvenlafaxine Succinate
Dosage Form
Tablet, Film Coated, Extended Release - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
DESVENLAFAXINE SUCCINATE 25 mg/1
Pharmacologic Class
Usage Information
Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Regulatory & Marketing

Labeler Name
Lupin Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA204172
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-25-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68180-604-06 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Desvenlafaxine Succinate, a human prescription drug labeled by Lupin Pharmaceuticals, Inc.. This tablet, film coated, extended release is formulated for oral use and contains desvenlafaxine succinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals, Inc. on August 25, 2022. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

How is this Lupin Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68180060406. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68180-604-06
11-Digit CMS (5-4-2)
68180-0604-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.